Cancer vaccine adjuvants - Recent clinical progress and future perspectives

Abid H. Banday, Salika Jeelani, Victor J Hruby

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Despite recent breakthroughs in the prognosis, prevention and treatment, cancer still remains the leading cause of death and affects millions of people worldwide. With the US FDA approval of various preventive cancer vaccines such as Gardasil (Merck), Cervarix (Glaxosmithkline) and the therapeutic vaccine Sipulencel-T (Provenge), cancer vaccine development is gaining huge ground. Approval of these vaccines has encouraged the concept of cancer treatment through cellular immunotherapy. The FDA approval of the above vaccines has provided support for renewed interest and attention which the development of new therapeutic cancer vaccines deserves. However, most of the new generation vaccines including that for cancer are poorly immunogenic sub-unit vaccines and thus essentially need adjuvants in their formulations to compensate for the immune suppression. Adjuvants are the essential components of a potent vaccine which increases the efficacy by enhancing the antigen-specific immune response. However, the design of a successful adjuvant is not easy because of the complexity and the difficulty in designing adjuvants that are safe, potent and economically viable. The present communication takes a short review of the advancements in adjuvant technology, current clinical scenario of new adjuvants and application of their molecularly defined formulations to new generation cancer vaccines which are currently under development.

Original languageEnglish (US)
Pages (from-to)1-11
Number of pages11
JournalImmunopharmacology and Immunotoxicology
Volume37
Issue number1
DOIs
StatePublished - Feb 1 2015

Fingerprint

Cancer Vaccines
Vaccines
Oncology
Histocompatibility Antigens Class II
Therapeutics
Immunotherapy
Cause of Death
Neoplasms
Technology
Antigens
Communication

Keywords

  • Antigen
  • Antigen presentation
  • Cancer immunotherapy
  • Immune adjuvant
  • Subunit vaccines

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology
  • Toxicology

Cite this

Cancer vaccine adjuvants - Recent clinical progress and future perspectives. / Banday, Abid H.; Jeelani, Salika; Hruby, Victor J.

In: Immunopharmacology and Immunotoxicology, Vol. 37, No. 1, 01.02.2015, p. 1-11.

Research output: Contribution to journalArticle

@article{b26d8b7f2d9a4c0ab2134c84cda25357,
title = "Cancer vaccine adjuvants - Recent clinical progress and future perspectives",
abstract = "Despite recent breakthroughs in the prognosis, prevention and treatment, cancer still remains the leading cause of death and affects millions of people worldwide. With the US FDA approval of various preventive cancer vaccines such as Gardasil (Merck), Cervarix (Glaxosmithkline) and the therapeutic vaccine Sipulencel-T (Provenge), cancer vaccine development is gaining huge ground. Approval of these vaccines has encouraged the concept of cancer treatment through cellular immunotherapy. The FDA approval of the above vaccines has provided support for renewed interest and attention which the development of new therapeutic cancer vaccines deserves. However, most of the new generation vaccines including that for cancer are poorly immunogenic sub-unit vaccines and thus essentially need adjuvants in their formulations to compensate for the immune suppression. Adjuvants are the essential components of a potent vaccine which increases the efficacy by enhancing the antigen-specific immune response. However, the design of a successful adjuvant is not easy because of the complexity and the difficulty in designing adjuvants that are safe, potent and economically viable. The present communication takes a short review of the advancements in adjuvant technology, current clinical scenario of new adjuvants and application of their molecularly defined formulations to new generation cancer vaccines which are currently under development.",
keywords = "Antigen, Antigen presentation, Cancer immunotherapy, Immune adjuvant, Subunit vaccines",
author = "Banday, {Abid H.} and Salika Jeelani and Hruby, {Victor J}",
year = "2015",
month = "2",
day = "1",
doi = "10.3109/08923973.2014.971963",
language = "English (US)",
volume = "37",
pages = "1--11",
journal = "Immunopharmacology and Immunotoxicology",
issn = "0892-3973",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Cancer vaccine adjuvants - Recent clinical progress and future perspectives

AU - Banday, Abid H.

AU - Jeelani, Salika

AU - Hruby, Victor J

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Despite recent breakthroughs in the prognosis, prevention and treatment, cancer still remains the leading cause of death and affects millions of people worldwide. With the US FDA approval of various preventive cancer vaccines such as Gardasil (Merck), Cervarix (Glaxosmithkline) and the therapeutic vaccine Sipulencel-T (Provenge), cancer vaccine development is gaining huge ground. Approval of these vaccines has encouraged the concept of cancer treatment through cellular immunotherapy. The FDA approval of the above vaccines has provided support for renewed interest and attention which the development of new therapeutic cancer vaccines deserves. However, most of the new generation vaccines including that for cancer are poorly immunogenic sub-unit vaccines and thus essentially need adjuvants in their formulations to compensate for the immune suppression. Adjuvants are the essential components of a potent vaccine which increases the efficacy by enhancing the antigen-specific immune response. However, the design of a successful adjuvant is not easy because of the complexity and the difficulty in designing adjuvants that are safe, potent and economically viable. The present communication takes a short review of the advancements in adjuvant technology, current clinical scenario of new adjuvants and application of their molecularly defined formulations to new generation cancer vaccines which are currently under development.

AB - Despite recent breakthroughs in the prognosis, prevention and treatment, cancer still remains the leading cause of death and affects millions of people worldwide. With the US FDA approval of various preventive cancer vaccines such as Gardasil (Merck), Cervarix (Glaxosmithkline) and the therapeutic vaccine Sipulencel-T (Provenge), cancer vaccine development is gaining huge ground. Approval of these vaccines has encouraged the concept of cancer treatment through cellular immunotherapy. The FDA approval of the above vaccines has provided support for renewed interest and attention which the development of new therapeutic cancer vaccines deserves. However, most of the new generation vaccines including that for cancer are poorly immunogenic sub-unit vaccines and thus essentially need adjuvants in their formulations to compensate for the immune suppression. Adjuvants are the essential components of a potent vaccine which increases the efficacy by enhancing the antigen-specific immune response. However, the design of a successful adjuvant is not easy because of the complexity and the difficulty in designing adjuvants that are safe, potent and economically viable. The present communication takes a short review of the advancements in adjuvant technology, current clinical scenario of new adjuvants and application of their molecularly defined formulations to new generation cancer vaccines which are currently under development.

KW - Antigen

KW - Antigen presentation

KW - Cancer immunotherapy

KW - Immune adjuvant

KW - Subunit vaccines

UR - http://www.scopus.com/inward/record.url?scp=84918809784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918809784&partnerID=8YFLogxK

U2 - 10.3109/08923973.2014.971963

DO - 10.3109/08923973.2014.971963

M3 - Article

VL - 37

SP - 1

EP - 11

JO - Immunopharmacology and Immunotoxicology

JF - Immunopharmacology and Immunotoxicology

SN - 0892-3973

IS - 1

ER -